Trial · NCT05052229
Inhaled Nitric Oxide (iNO) in Idiopathic Pulmonary Fibrosis (IPF).
NCT05052229, Early phase 1, Unknown, Dr. Denis O'Donnell
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Inhaled Nitric Oxide (iNO) in Idiopathic Pulmonary Fibrosis (IPF). Trials, record NCT05052229. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05052229
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Inhaled Nitric Oxide (iNO) in Idiopathic Pulmonary Fibrosis (IPF).
- NCT number
- NCT05052229
- Status
- Unknown
- Phases
- Early phase 1
- Enrollment
- 40 participants, estimated
- Lead sponsor
- Dr. Denis O'Donnell
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Nitric Oxide, Medical air
- First posted
- 2021-09-22
- Last updated
- 2024-04-03
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Ventilatory efficiency (VE/VCO2) | During exercise test on visit 4 and 5, every 1 minute, through end-exercise (average time 6-10minutes). | Ventilatory efficiency will be measured by expired gas analysis. Measurements will be collected on a breath-by breath basis and compared with predicted values based on age and height. Three main time points will be evaluated: "rest" will be defined as the steady-state period after at least 3 minutes of breathing on the mouthpiece before exercise starts; "isotime" will be defined as the last 30-sec increment of each minute (i.e. 1-min, 2-min, 3-min) during the incremental exercise test and at 2 minutes (or the longest time achieved by all subjects) during the constant load exercise tests, and; "end-exercise" will be defined as the last 30-sec of loaded pedaling. |
| Primary | Inspiratory Neural Drive (IND) as measured by Diaphragmatic electromyography (EMGdi) | During exercise test on visit 4 and 5, every 1 minute, through end-exercise (average time 6-10minutes). | An esophageal electrode-balloon catheter consisting of 5 electrode pairs and two balloons, will be inserted nasally and positioned for optimal recoding. Electromyogram output of the diaphragm (used as an index of inspiratory neural drive to crural diaphragm or diaphragm activation; EMGdi) will be recorded continuously at rest and during exercise. Maximal EMGdi (EMGdi,max) will be determined from inspiratory capacity (IC) maneuvers. EMGdi/EMGdi,max will be used as an index of the inspiratory neural drive to the crural diaphragm. |
| Secondary | Dyspnea Intensity | During exercise test on visit 4 and 5, every 1 minute, through end-exercise (average time 6-10minutes). | Dyspnea (respiratory discomfort) will be defined as the "sensation of breathing discomfort" experienced at rest and during pedaling. Measurements will be made at rest (the steady-state period after at least 3 minutes of breathing on the mouthpiece before exercise starts), at two-minute intervals during exercise, and at end-exercise (at 2 minutes or the last 30-sec of loaded pedaling achieved by all the participants). The intensity (strength) of sensations will be rated using the modified 10-point Borg scale. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers6
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05052229
GET https://conductscience.org/api/trials/v1/NCT05052229/registered